Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Next Previous
Trial Profile

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 27 May 2025 According to BriaCell Therapeutics Corp media release, this trial has cleared its safety evaluation and has now transitioned to dosing patients in combination with a checkpoint inhibitor (CPI).Also The first patient has been dosed in this study.
  • 23 May 2025 According to a BriaCell Therapeutics Corp media release, data from this study will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • 24 Apr 2025 According to a BriaCell Therapeutics media release, the company confirms the sustained complete resolution of the lung metastasis, first reported in February 2025, two months after initial treatment in the ongoing Phase 1/2 Bria-OTS study. The latest data at four months also demonstrates stable disease elsewhere

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top